Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Just want to send this found it interesting .. http://abc7.com/news/napster-co-founder-sean-parker-bankrolls-project-to-speed-cancer-work/1289236/
Thanks I've placed it in the Pyle of hopefuls but knee deep in it
Are we holding for a merger at this point?
Well I'm stuck I'm Not giving up now ..
Well just my luck I took a look on a bad day ... No wait its Armageddon .. I guess buying on the last dip wasn't a good decision .. I Dont know how much more pain I can't take to the pocket .. My view, I've got a bin full of coins .. The way I see it this was like walking to the trash bin and dumping them in the trash never to be seen again.
I'll be watching close at the open ...
How does this affect us
http://mobile.reuters.com/article/idUSKCN0RW20W20151002
Sorry to intrude on your message ... Still here guys
We are closer by the day. The excitement is building! The negative post will build with intent to destroy .. But they can't destroy FACTS .. See you at the finish line
Well Put awesome! Statement of A True Long .... I'm Hanging on for dear Life .. I let another stock get away from me years ago FONAR ... SOLD IT ALL FOR FOR A LOSS .. THEN BANG! IT TOOK OFF ... NEVER AGAIN
Hop skip and a jump for me, I'm already here . I've driven by multiple times .. Can't wait to toot my horn with a big thank you some day!
Love it go CJ its got my vote! I say put you on the board too!
Hello MD... I've been waiting quietly .. When I discovered this we must be getting close if others in the industry are doing well .. Bristol... seems to have
It figured out .. Can you or any others open up our minds as to what our differences are and what will bring us out of dollar land???
Here's the article that has me coming out of hibernation...
FDA News Release
Hello MD... I've been waiting quietly .. When I discovered this we must be getting close if others in the industry are doing well .. Bristol... seems to have
It figured out .. Can you or any others open up our minds as to what our differences are and what will bring us out of dollar land???
FDA News Release
FDA expands approved use of Opdivo to treat lung cancer
For Immediate Release
March 4, 2015
Release
Español
The U.S. Food and Drug Administration today expanded the approved use of Opdivo (nivolumab) to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.
Lung cancer is the leading cause of cancer death in the United States, with an estimated 224,210 new diagnoses and 159,260 deaths in 2014. The most common type of lung cancer, NSCLC affects seven out of eight lung cancer patients, occurring when cancer forms in the cells of the lung.
Opdivo works by inhibiting the cellular pathway known as PD-1 protein on cells that blocks the body’s immune system from attacking cancerous cells. Opdivo is intended for patients who have previously been treated with platinum-based chemotherapy.
“The FDA worked proactively with the company to facilitate the early submission and review of this important clinical trial when results first became available in late December 2014,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “This approval will provide patients and health care providers knowledge of the survival advantage associated with Opdivo and will help guide patient care and future lung cancer trials.”
Opdivo’s efficacy to treat squamous NSCLC was established in a randomized trial of 272 participants, of whom 135 received Opdivo and 137 received docetaxel. The trial was designed to measure the amount of time participants lived after starting treatment (overall survival). On average, participants who received Opdivo lived 3.2 months longer than those participants who received docetaxel.
The safety and efficacy of Opdivo to treat squamous NSCLC was supported by a single-arm trial of 117 participants who had progressed after receiving a platinum-based therapy and at least one additional systemic regimen. The study was designed to measure objective response rate (ORR), or the percentage of participants who experienced partial shrinkage or complete disappearance of the tumor. Results showed 15 percent of participants experienced ORR, of whom 59 percent had response durations of six months or longer.
The most common side effects of Opdivo are fatigue, shortness of breath, musculoskeletal pain, decreased appetite, cough, nausea and constipation. The most serious side effects are severe immune-mediated side effects involving healthy organs, including the lung, colon, liver, kidneys and hormone-producing glands.
Opdivo for squamous NSCLC was reviewed under the FDA’s priority review program, which provides for an expedited review of drugs that treat serious conditions and, if approved, would provide significant improvement in safety or effectiveness in the treatment of a serious condition. Opdivo is being approved more than three months ahead of the prescription drug user fee goal date of June 22, 2015, the date when the agency was scheduled to complete its review of the application.
The FDA previously approved Opdivo to treat patients with unresectable (cannot be removed by surgery) or metastatic melanoma who no longer respond to other drugs.
Opdivo is marketed by Princeton, New Jersey-based Bristol-Myers Squibb.
The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.
Here's the article that has me coming out of hibernation...
FDA News Release
Charter cable internet phones sales dept under construction email 1800charter@gmail.com a service rep will call you back.
Charter Cable Internet Phone Sales Dept under Construction email 1800charter@gmail.com a service rep will call you back.
With a few of the best of ya aren't going, Who should I meet up with to
Chat and Gather information with..
Anyone in particular...?
I take it no dinner meeting Thursday night ?
18000 von karman ave ca 92612
Dukes boy and wife will be there looking up address now
Count me in ASM
Another watch and wait Day :-/
CHARTER COMMUNICATIONS SPEEDS ON THE WAY UP!
Seeking Customers Questions Regarding Service Email: 888GETCHARTER@GMAIL.COM
To Receive Special Discount Offers for New Customers, Type in Heading
( I NEED SERVICE )
Seeking Customers Questions Regarding Service.
Email:
888GETCHARTER@GMAIL.COM
To Receive Special Discount Offers for New Customers, Type in Heading
( I NEED SERVICE )
Seeking Customers Questions Regarding Service.
Email:
888GETCHARTER@GMAIL.COM
To Receive Rpecial Discount Offers for New Customers, Type in Heading
( I NEED SERVICE )
Why these 3 biotech stocks are making big moves
http://www.cnbc.com/id/101721186
And not a mention of us ?
http://www.ncsd.org/
National Cancer Survivors Day
June 1 2014
My daily peek looks good today
Should have bought more before vacation oops
hanging in there for the good times! Adding more soon
So true Pphm addiction. I call it
I can't begin to tell you how many time caught driving to work (still dark outside ) my screen on ihub/cnbc; as motorcycle cop pulls me over to tell me it's not safe to use my phone and drive ( here is your ticket )
Leaving me to sell a few shares to pay for my ( Pphm addiction )
Merck halts study of the billion-dollar cancer drug vintafolide ...
www.fiercebiotech.com/.../merck...
by Damian Garde - in 42 Google+ circles
9 hours ago - Merck snags rights to Endocyte's ovarian cancer drug in $1B deal ... Breakfast: Facing the Proof of Concept ChallengeJune 18, 2014 — San Diego, CA — Sponsored by Appian &
Thanks wookie may the fourth be with you 5/4/14
I need it to lay low a little longer
Expected windfall coming my way
Cool sport been around awhile
Not as long as others but sure is nice to find the real deal
Gather what ya can while it's cheap
Now we can go forward for sure now that the closet is clean out
You bet $1.60 my magic # as well
Not sure how much going to buy yet
But my fortune cookie said this is the year to " invest in my future for great returns" and wouldn't you know it my palms a itchin!
I could use another 10,000 shares
Please.
GLTA
I'm in late guys was told pphmp all shares sold ???? Info please
Android eatquake warning app / locator is cool